Apimeds Pharmaceuticals US (APUS) Current Assets (2023 - 2026)

Apimeds Pharmaceuticals US (APUS) has reported Current Assets for 4 consecutive years, with $10.7 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Current Assets rose 3.18% year-over-year to $10.7 million; the trailing twelve-month figure through Jun 2026 stood at $10.7 million (up 3.18% YoY), and the FY2025 full-year result was $14.0 million, up 106998.56% from the prior year.
• Current Assets eased to $10.7 million in Q2 2026 per APUS's latest filing, from $14.0 million in the prior quarter.
• Across five years, Current Assets topped out at $14.0 million in Q4 2025 and bottomed at $13057.0 in Q4 2024.
• Historically, Current Assets has averaged $6.4 million across 4 years, with a median of $9.1 million in 2025.
• The sharpest annual moves came in 2024 and 2025: Current Assets slumped 96.91% in 2024, then jumped 106998.56% in 2025.
• Over 4 years, Current Assets stood at $422076.0 in 2023, then plunged by 96.91% to $13057.0 in 2024, then surged by 106998.56% to $14.0 million in 2025, then slipped by 23.64% to $10.7 million in 2026.
• According to Business Quant data, Current Assets over the past three periods registered $10.7 million, $14.0 million, and $9.1 million for Q2 2026, Q4 2025, and Q3 2025 respectively.